Pharmbio Korea said Tuesday that Ferring Pharmaceuticals, a multi-national pharmaceutical company, has obtained U.S. Food and Drug Administration’s (FDA) approval for Picosolution, the world’s first ready-to-drink (RTD) colonoscopy preparation solution.
Picosolution is an improved drug of Ferring Pharmaceutical’s Prepopik, a powdered colonoscopy preparation solution. The treatment rectified the inconvenience of existing powdered colonoscopy preparation that required a patient to drink large amounts of water.
The company exported the stable liquid formulation used in Picosolution back to Ferring Pharmaceuticals for 42.5 billion won ($39.1 million) last year. Ferring plans to market the product as Clenpiq in the global market, while Pharmbio Korea will be in charge of marketing Picosolution in Korea.
“Compliance and efficacy are important when patients choose colonoscopy preparation solutions,” said Woo Dong-wan, managing director of Pharmbio Korea’s marketing department. “Picosolution has expanded prescription options for physicians and is increasing its prescription after confirming high patient compliance.”